证券代码：300267 证券简称：尔康制药 公告编号：2023-017 特此公告！ 湖南尔康制药股份有限公司（以下简称"公司"）已于2023年4月27日对外 披露《2022年年度报告》及其摘要，为了方便广大投资者更好、更深入地了解公 司经营情况，公司将于2023年5月12日（星期五）下午15:00-17:00举办2022年度 业绩网上说明会。本次年度业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（http://rs.p5w.net）参与本次年度业绩说明会。 出席本次年度报告说明会的人员有：公司董事长帅放文先生，董事会秘书顾 吉顺先生，董事、财务总监赵寻女士，独立董事代表谭雪先生。 为充分尊重投资者、提升交流的针对性，公司2022年度业绩说明会向投资者 公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5月11日前访 问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面。敬请广大投 资者通过全景网系统提交您所关注的问题，便于公司在业绩说明会上对投资者普 遍关注的问题进行回答，以便提升此次业绩说明会效率。此次活动交流期间，投 资者仍可登陆 ...

Group 1: Market Demand and Growth - The demand for hard capsules in China reached approximately 250 billion to 300 billion units by the end of 2013, with soft capsules at about 50,000 tons annually [2] - The capsule industry is expected to maintain an annual growth rate of around 15% during the "12th Five-Year Plan" period, resulting in an annual increase of approximately 20 billion capsules [2] Group 2: Research and Standards - The company has participated in the development of over 50 pharmaceutical excipient standards for the 2015 edition of the Pharmacopoeia of China, including various starches and other materials [3] - The public announcement period for the pharmaceutical excipient standards is three months [3] Group 3: Project Investment and Progress - The company invested 504.35 million yuan in the construction of a tapioca starch hollow capsule industrial park, with an expected annual production capacity of 30 billion capsules [3] - The project is progressing smoothly and is on track to meet production targets, barring any weather-related disruptions [3] Group 4: Financial Performance - In the first half of 2014, the revenue from pharmaceutical sucrose products increased by 127.64% compared to the same period last year, while the revenue from injectable sulbenicillin sodium products grew by 71.23% [3] Group 5: Market Feedback - Tapioca starch capsules are more widely accepted by consumers compared to gelatin capsules made from animal sources, appealing to groups such as Muslims, Hindus, and vegetarians [3] - There is growing interest from domestic and international clients regarding the company's starch capsule products [3]

Group 1: Company Position and Market Overview - The company is the world's first industrial producer of starch capsules and the only entity in China with a "National Engineering Research Center for Pharmaceutical Excipients" [2] - The company holds 39 national authorized patents and has stable partnerships with over 3,000 pharmaceutical companies across more than 30 provinces and cities in China [2][3] Group 2: Project Details - The non-public stock issuance project aims to produce 100 billion starch plant capsules and 30 billion starch plant soft capsules annually [2] - The total investment for the project is 2.5 billion RMB, with a construction period of 2 years [3] - Upon completion, the project is expected to generate an annual sales revenue of 3.84 billion RMB and a net profit of 1.3 billion RMB, indicating strong profitability and investment recovery potential [3] Group 3: Product Advantages - The starch plant capsules are made from 100% natural starch, ensuring safety and eliminating risks associated with animal-derived materials [3] - The capsules do not undergo cross-linking reactions, making them safe for use with common chemical drugs and traditional Chinese medicine [3] - The production process avoids any chemical additives, preservatives, or colorants, enhancing product safety [3] - The stability of the capsules is high due to their single-component structure, which is less prone to bacterial growth and spoilage [3] - The company has a subsidiary in Cambodia that produces 180,000 tons of cassava starch annually, ensuring a steady supply of raw materials for capsule production [3] Group 4: Marketing Strategy - The company employs a distributor-first sales model, leveraging existing sales networks of local distributors for rapid product promotion [4]

编号：2015-008 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □路演活动 | | | ...

编号：2015-003 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 中金公司 邹朋 | | | 时间 | 2015 年 6 月 8 日 | | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | 董事会秘书 罗琅 | | | 投资者关系活动主要内容 介绍 | | 调研机构与公司交流内容如下： | | | ...

编号：2015-007 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------| | | | | | | □ | 媒体采访 □业绩说明会 | | 投资 ...

Group 1: Product Advantages - The starch capsules are made from 100% natural starch and purified water, ensuring safety and non-toxicity [3] - The capsules do not undergo cross-linking reactions, making them chemically inert and safe for use with common pharmaceuticals [3] - No chemical additives such as preservatives or colorants are used in the production process [3] - The stability of the starch capsules is high due to their simple molecular structure, which is less prone to bacterial growth and spoilage [3] - The company has a subsidiary in Cambodia that produces 180,000 tons of cassava starch annually, ensuring a stable supply of raw materials for capsule production [3] Group 2: Market Potential - The global capsule market has a total production of over 1.4 trillion units in 2014, with gelatin capsules accounting for 95% of this market [4] - There are approximately 1.6 billion Muslims, 1 billion Hindus, and a growing number of vegetarians globally, creating a wider audience for starch capsules [4] - The company’s starch capsules have received certifications from the EU Vegetarian Society, Clean Certification, and Kosher Certification, enhancing market competitiveness [4] - The future application of capsules is expected to expand, as they are easier to swallow and can shorten the time to market for pharmaceuticals [4] Group 3: Sales Strategy - The company employs a multi-channel sales strategy, combining online and offline methods, including e-commerce, B2B sales, and overseas markets [3] - The current selling price of starch capsules through e-commerce platforms is 0.32 yuan per capsule, indicating a high added value [4] Group 4: Strategic Development - The company is working on a non-public offering project, currently in the review and feedback stage by the regulatory authority [5] - The establishment of an internet-based trading service platform for pharmaceutical excipients aims to enhance supply chain management and customer satisfaction [5] - The company has successfully overcome technical barriers in the industrialization of starch plant capsules, establishing a complete industrial chain from raw materials to end sales [5][6]

编号：2014-002 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------|----------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 易方达 赵锴 | 杨桢霄 付浩 | | | 中国银河证券 中信建投 刘永越 鼎睿投资 肖翔 其他个人投资者 | 张金洋 冀叶银 刘玺 齐琪 苏徐 周员发 | | 时间 | 2015 年 5 月 29 | 日 下午 16:30-18:00 | | 地点 | 公司会议室 | | | 上市公 ...

编号：2016-001 证券代码：300267 证券简称：尔康制药 湖南尔康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 □其他 | □路演活动 （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 1、中信证券 2 、中信证券 3 、中信证券 4 5 | 冷小梅 田加强 陈竹 、汇添富基金管理股份有限公司 谭志强 、汇添富基金管理股份有限公司 付鹏飞 6、汇添富基 ...